Patents Assigned to Inserm
  • Methods for cancer management targeting Co-029
    Patent number: 9040671
    Abstract: The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: May 26, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Paris X1 Paris Sud
    Inventors: Eric Rubinstein, Céline Greco, François Le Naour, Claude Boucheix
  • Bioprinting station, assembly comprising such bioprinting station and bioprinting method
    Patent number: 9039998
    Abstract: Bioprinting station (1) comprising:—a Bioprinting device (4) adapted to deposit a pattern of biological material (2) onto an area of interest (3a) of a substrate (3),—an imaging system (15) adapted to acquire an image of the substrate (3) and to reveal on the acquired image the area of interest (3a) with respect to a remaining part (3b) of the substrate (3), the acquired image of the substrate (3) being processed so as to detect the revealed area of interest (3a) on the acquired image and to determine the pattern corresponding to the area of interest (3a) detected on the acquired image.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: May 26, 2015
    Assignee: Institut National de la Sante et de la Recherche Medical (INSERM)
    Inventors: Fabien Guillemot, Sylvain Catros, Virginie Keriquel, Jean-Christophe Fricain
  • METHODS FOR DIAGNOSING AND TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS
    Publication number: 20150140010
    Abstract: The present invention relates to methods for diagnosing and treating focal segmental glomerulosclerosis. More particularly, the present invention relates to a method for determining whether a subject is at risk of having or developing a focal segmental glomerulosclerosis (FSGS) comprising the step consisting of determining the level of calcium/calmodulin-dependent serine protein kinase (CASK) in a blood sample obtained from the subject. The present invention also relates to an agent effective to inhibit the binding of CASK to hCD98 present on the surface of podocytes for use in the prevention or treatment of focal segmental glomerulosclerosis (FSGS) in a subject in need thereof.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 21, 2015
    Applicants: INSERM 9INSTITUT NATIONAL DE LA SANTE ET DE LA R- ECHERCHE MEDICALE), UNIVERSITE PARIS-SUD XI, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Inventors: Antoine Durrbach, Hanz Lorenzo, Severine Beaudreuil
  • Radioactive Rhodium Complexes, Preparation Methods and Uses Thereof
    Publication number: 20150139901
    Abstract: The present invention concerns radioactive rhodium complexes, their preparation methods, and their use for the radiolabelling of biomolecules, especially monoclonal antibodies.
    Type: Application
    Filed: May 14, 2013
    Publication date: May 21, 2015
    Applicants: Institut National de la Sante et de la Recherche (INSERM), Chu Nantes, Universite de Nantes, Centre National de la Recherche Scientifique (C.N.R.S.), Universite d' Angers
    Inventors: Alain Faivre-Chauvet, Holisoa Rajaerison, Jean-Francois Gestin
  • METHODS FOR DETECTING INACTIVATION OF THE HOMOLOGOUS RECOMBINATION PATHWAY (BRCA1/2) IN HUMAN TUMORS
    Publication number: 20150140122
    Abstract: The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 21, 2015
    Applicant: INSERM (Institut National de la Sante et de la Rec herche)
    Inventors: Marc-Henri Stern, Elodie Manie, Tatiana Popova
  • Nucleic acids targeting TCTP for use in the treatment of chemo- or hormone-resistant cancers
    Patent number: 9034840
    Abstract: The present invention concerns a TCTP antagonist, in particular a nucleic acid targeting an m RNA encoding Translationally-Controlled Tumor Protein (TCTP), wherein said nucleic acid is capable of reducing the amount of TCTP in cells, for use in the treatment or prevention of hormone-independent cancer or chemo-resistant cancer, such as an androgen-independent prostate cancer.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: May 19, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de la Mediterrance Aix-Marseille II
    Inventors: Palma Rocchi, Virginie Baylot, Julie Acunzo, Claudia Andrieu, Maria Katsogiannou
  • Modified gram-negative bacteria for use as vaccines
    Patent number: 9034630
    Abstract: The invention relates to Gram-negative bacteria carrying an inactivated gene encoding a glycosyltransferase involved in the synthesis of the core of the LPS of said Gram-negative bacteria, wherein said inactivated gene results in the synthesis of a LPS having a modified core. These strains have an attenuated virulence but induce a humoral immunity sufficient for ensuring vaccination of the host.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: May 19, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique—CNRS, Université d'Aix Marseille, UNIVERSIDAD DE NAVARRA
    Inventors: Jean-Pierre Gorvel, Vilma Arce Gorvel, Maite Iriarte, Ignacio Moriyon, Raquel Conde-Alvarez
  • NOVEL MELANOMA ANTIGEN PEPTIDE AND USES THEREOF
    Publication number: 20150132329
    Abstract: The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.
    Type: Application
    Filed: May 22, 2012
    Publication date: May 14, 2015
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'ANGERS
    Inventors: Nathalie Labarriere, Francois Lang, Mathilde Bobinet, Anne Rogel
  • METHOD FOR THE DIAGNOSIS OF EARLY RHEUMATOID ARTHRITIS
    Publication number: 20150133322
    Abstract: The present invention relates to biomarkers that are specifically recognized by autoantibodies present in a biological of patients with Rheumatoid Arthritis (RA). The invention provides methods and kits using these biomarkers for the diagnosis of RA, in particular for the diagnosis of early RA.
    Type: Application
    Filed: May 11, 2012
    Publication date: May 14, 2015
    Applicant: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Jean Roudier, Isabelle Auger
  • METHODS FOR THE DIAGNOSIS AND THE TREATMENT OF FAMILIAL THORACIC AORTIC ANEURYSMS CAUSED BY TGFB2 LOSS OF FUNCTION MUTATIONS
    Publication number: 20150133381
    Abstract: The present invention relates to methods for the diagnosis and the treatment of familial thoracic aortic aneurysms caused by TGFB2 loss of function mutations. More particularly, the present invention relates to a method for determining whether a subject is predisposed to thoracic aortic aneurysms comprising detecting a TGFB2 loss of function mutation wherein the presence of the mutation indicated that the subject is predisposed to thoracic aortic aneurysms. The present invention also relates to a transforming growth factor beta-2 (TGF-?2) polypeptide for use in the prophylactic treatment of a subject who has been considered as predisposed to thoracic aortic aneurysms by the method of the invention (i.e. a subject having one TGB2 loss of function mutation according to the invention).
    Type: Application
    Filed: May 15, 2013
    Publication date: May 14, 2015
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Catherine Boileau, Dianna Milewicz, Guillaume Jondeau
  • Method and kits for determining platelet susceptibility to activation in a patient
    Patent number: 9029095
    Abstract: The invention relates to methods and kits for determining platelet susceptibility to activation in a patient. More particularly, the present invention relates to a method for determining platelet susceptibility to activation in a patient, comprising a step consisting of measuring the level of GPVI dimers at the platelet surface in a blood sample obtained from said patient.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: May 12, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Diderot
    Inventors: Martine Jandrot-Perrus, Laurent Feldman, Stéphane Loyau
  • Kanamycin antisense nucleic acid for the treatment of cancer
    Patent number: 9029135
    Abstract: The invention relates to a nucleic acid comprising a sequence complementary to a fragment of the sequence coding for the kanamycin resistance protein. This nucleic acid is useful as a DNA vaccine adjuvant, and can be used e.g. for treating cancer, for example in combination with a non-immunosuppressive inducer of tumor cell apoptosis such as all-trans retinoic acid (ATRA).
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: May 12, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (Inserm), Universite Paris Diderot-Paris 7
    Inventors: Rose Ann Padua, Christine Chomienne
  • Method for preparing porous scaffold for tissue engineering
    Patent number: 9028857
    Abstract: The present invention relates to a method for preparing a porous scaffold for tissue engineering. It is another object of the present invention to provide a porous scaffold obtainable by the method as above described, and its use for tissue engineering, cell culture and cell delivery. The method of the invention comprise the steps consisting of a) preparing an alkaline aqueous solution comprising an amount of at least one polysaccharide and one cross-linking agent b) freezing the aqueous solution of step a) c) sublimating the frozen solution of step b). characterized in that step b) is performed before the cross-linking of the polysaccharide occurs in the solution of step a).
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: May 12, 2015
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris 7—Denis Diderot
    Inventors: Catherine Le Visage, Didier Letourneur, Frederic Chaubet, Aude Autissier
  • Inhibitors of the PP1/GADD34 Complex for the Treatment of a Condition Requiring an Immunosuppressive Activity
    Publication number: 20150126549
    Abstract: The present invention relates to the general field of the treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the of treatment an immunosuppressive activity namely autoimmune diseases and graft rejection. In particular, the invention relates to an inhibitor of the activity or the formation of the PP1/GADD34 complex for the treatment of a condition requiring an immunosuppressive activity or an anti-inflammatory activity.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 7, 2015
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite d'Aix-Marseille
    Inventor: Philippe Pierre
  • ASXL1 AS A NEW DIAGNOSTIC MARKER OF MYELOID NEOPLASMS
    Publication number: 20150125868
    Abstract: The present invention relates to a method for diagnosing a myeloid cancer in a subject, which comprises the step of analyzing a biological sample from said subject by determining the presence or the absence of a mutation in the ASXL1 (additional sex combs like 1) gene coding for the polypeptide having the sequence SEQ ID No 2. A kit for diagnosing myeloid cancer in a subject comprising at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a such a method.
    Type: Application
    Filed: October 10, 2014
    Publication date: May 7, 2015
    Applicants: Qiagen Marseille SA, Institut Paoli-Calmettes, INSERM (Institut National de la Santé et de la Recherche Médicale)
    Inventors: VÉRONIQUE GELSI-BOYER, DANIEL BIRNBAUM
  • Peptide capable of altering tubulin polymerization and use thereof for inhibiting cell proliferation
    Patent number: 9023806
    Abstract: The invention concerns a peptide derived from intermediate filaments and an intermediate filament fragment capable of altering tubulin polymerization and used for inhibiting cell proliferation, and more particularly for obtaining medicines designed to prevent or treat diseases involving cell proliferation, such as cancers for example.
    Type: Grant
    Filed: April 21, 2005
    Date of Patent: May 5, 2015
    Assignees: Universite d'Angers, Institut National de la Sante et de la Recherche Medicale (Inserm), McGill University
    Inventors: Arnaud Bocquet, Joël Eyer, Alan Peterson
  • 28 KDA GST PROTEINS FROM SCHISTOSOMA FOR THE USE THEREOF IN THE TREATMENT OF INFLAMMATORY AUTOIMMUNE DISEASES GENERATING A TH1 AND/OR TH17 RESPONSE
    Publication number: 20150118259
    Abstract: The present invention relates to a product selected from a protein, a fragment of the protein, a derived sequence and a homologous sequence of the protein, the protein including or being constituted by the 28 kDa glutathione S-transferase protein from a schistosome selected from Schistosoma haematobium, Schistosoma mansoni, Schistosoma bovis represented respectively by the sequences SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 for the use thereof in the treatment of an inflammatory autoimmune disease generating a response of type Th1 and/or Th17.
    Type: Application
    Filed: February 6, 2013
    Publication date: April 30, 2015
    Applicants: UNIVERSITE DU DROIT ET DE LA SANTE DE LILLE 2, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE
    Inventors: Monique Capron, Mohamed El Nady, Jean-Frederic Colombel, Gilles Riveau
  • Importation of mitochondrial protein by an enhanced allotopic approach
    Patent number: 9017999
    Abstract: The inventors demonstrate that mRNA sorting to the mitochondrial surface is an efficient way to proceed to such an allotopic expression, and that this mRNA sorting can be controlled by selecting appropriate mitochondrion-targeting sequence (MTS) and appropriate 3?UTR sequences. The CDS sequence which codes for the protein to be delivered into the mitochondrion is guided by these appropriate MTS and 3?UTR sequences from the nuclear compartment to the mitochondrion-bound polysomes (where the CDS is translated), and aids in an efficient translocation of a mature functional protein into the mitochondria. Appropriate MTS and 3?UTR sequences correspond to those of nuclearly-transcribed mitochondrially-targeted mRNAs. The inventors demonstrate that, to obtain a stable therapeutically-effective importation, both an appropriate MTS and an appropriate 3?UTR should preferably be used.
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: April 28, 2015
    Assignee: Institut National de la Sante et de la Recherche Medicale (Inserm)
    Inventors: Marisol Corral-Debrinski, Jose-Alain Sahel, Valerie Kaltimbacher, Crystel Bonnet
  • METHODS FOR THE TREATMENT OF LEBER CONGENITAL AMAUROSIS
    Publication number: 20150111951
    Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.
    Type: Application
    Filed: November 18, 2014
    Publication date: April 23, 2015
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), CNRS (Centre National de la Recherche Scientifique), Genethon, Universite Paris Descartes, ENSCP - Chimie ParisTech - Ecole Nationale Superieure de Chimie de Paris, Universite d'Evry-Val-d'Essonne, Assistance Publique Hopitaux De Paris
    Inventors: Jean-Michel ROZET, Antoine KICHLER, Isabelle PERRAULT, Josseline KAPLAN, Xavier GERARD, Daniel SCHERMAN, M. Arnold MUNNICH
  • Methods for the treatment of Leber congenital amaurosis
    Patent number: 9012425
    Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harboring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2291+1655 A>G CEP290 mRNA.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: April 21, 2015
    Assignees: INSERM (Institute National de la Sante et de la Recherche Medicale), CNRS (Centre National de la Recherche Scientifique), Genethon, Universite Paris Descartes, ENSCP—Chimie Paris Tech—Ecole National Superieure de Chimie de Paris, Universite d'Evry-Val-d'Essonne, Assistance Publique—Hopitaux de Paris
    Inventors: Jean-Michel Rozet, Antoine Kichler, Isabelle Perrault, Josseline Kaplan, Xavier Gerard, Daniel Scherman, M. Arnold Munnich